Results 311 to 320 of about 156,767 (359)
Some of the next articles are maybe not open access.
Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase
Thrombosis Research, 1987The activation of a native form of plasminogen (Glu-plg) by tissue plasminogen activator(t-PA) was enhanced when the plasma was clotted by the addition of thrombin or thrombin plus Ca++. Cross-linking of fibrin in the clotted plasma did not inhibit the fibrin-associated enhancement of the activation of plasminogen by t-PA.
Masaru Cho+3 more
openaire +3 more sources
Studies on the kinetics of plasminogen activation by tissue plasminogen activator
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1982The steady-state rate of plasminogen activation by tissue plasminogen activator has been determined at various plasminogen concentrations. A plasmin substrate method similar to that presented by Christensen and Müllertz (Biochim. Biophys. Acta 480 (1977) 257-281) was used.
openaire +3 more sources
Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator
Thrombosis Research, 1990Here experimental evidence is presented demonstrating that Lp(a) inhibits the activation of Pg by the physiologic activator tissue-type plasminogen activator (t-PA) bound to fibrinogen fragments. The competitive inhibition constant, Kie, of the Lp(a) inhibition is 22 nM, or 8.6 mg/dL which corresponds to normal plasma ...
Jay M. Edelberg+2 more
openaire +3 more sources
Claims on tissue plasminogen activator
Nature, 1989A 'master' patent on a recombinant protein product has twice been overturned in British courts. The consequences may be far-reaching.
openaire +3 more sources
Kinetic studies of plasminogen activation by epithelial tissue plasminogen activator
Blood Coagulation & Fibrinolysis, 1990Initial-rate kinetic studies of the activation of plasminogen by epithelial activator were performed in the absence and in the presence of fibrinogen and CNBr-digested fibrinogen, under assay conditions similar to those described by Hoylaerts et al. (J Biol Chem, 257, 2912, 1982).
A Electricwala, R J Ling, Atkinson T
openaire +3 more sources
Tissue Plasminogen Activator (tPA)
2015Tissue plasminogen activator (tPA) is used in the setting of acute ischemic stroke. tPA is also utilized for several additional thrombolytic indications, including acute MI, pulmonary embolism, and central venous catheter occlusion.
Juan E. Small+2 more
openaire +2 more sources
Efficacy and safety of tissue plasminogen activator
Neurosurgery, 1987Simple aspiration to remove acute intracerebral hematomas has been thwarted by the solidity of the clot. Urokinase, a first generation fibrinolytic agent, has been used to liquefy such clots with some success. Therefore, tissue plasminogen activator (t-PA), a second generation fibrinolytic drug that may be safer and more effective, was studied to ...
David Bernstein+4 more
openaire +3 more sources
Content of Tissue Activator of Plasminogen in Monkey Tissues
Thrombosis and Haemostasis, 1957SummaryThe content of the tissue activator of plasminogen in various organs from monkey is generally lower than in the corresponding human organs and approaches the concentration in the organs of other animals.
H. R Roberts, Tage Astrup
openaire +3 more sources
Thrombosis Research, 1988
Glu-plasminogen (Glu-plg), Lys-plg and Val442-plg (mini-plg) were activated by urokinase (UK), streptokinase (SK) or tissue plasminogen activator (t-PA). Their activation rates were kinetically analyzed. UK activated Lys-plg with smaller Km and nearly identical Vmax as Glu-plg.
Yoshiaki Sugawara+2 more
openaire +2 more sources
Glu-plasminogen (Glu-plg), Lys-plg and Val442-plg (mini-plg) were activated by urokinase (UK), streptokinase (SK) or tissue plasminogen activator (t-PA). Their activation rates were kinetically analyzed. UK activated Lys-plg with smaller Km and nearly identical Vmax as Glu-plg.
Yoshiaki Sugawara+2 more
openaire +2 more sources
Tissue Plasminogen Activator and the Corneal Endothelium
American Journal of Ophthalmology, 1989• There is a potential risk of bacterial or fungal contamination of the initial preparation, which could then result in contamination of each of the individual doses. It is essential, therefore, that the tissue plasminogen activator be reconstituted under strict aseptic conditions in a sterile hood.
Mark L. McDermott+3 more
openaire +3 more sources